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Abstract 
While efforts are made to improve tissue quality and control preanalytical variables, pathologists are often 
confronted with the challenge of molecular analysis of patient samples of unknown quality. Here we describe 
a first attempt to construct a tissue quality index (TQI) or an intrinsic control that would allow a global 
assessment of protein status based on quantitative measurement of a small number of selected, informative 
epitopes. Quantitative immunofluorescence (QIF) of a number of proteins was performed on a series of 93 
breast cancer cases where levels of expression were assessed as a function of delayed time to formalin 
fixation. A TQI was constructed based on the combination of proteins that most accurately reflect increased 
and decreased levels of expression in proportion to delay time. The TQI, defined by combinations of 
measurements of cytokeratin, ERK1/2 and pHSP-27 and their relationship to cold ischemic time were 
validated on a second build of the training series and on two independent breast tissue cohorts with recorded 
time to formalin fixation. We show an association of negative TQI values (an indicator for loss of tissue 
quality) with increasing cold ischemic time on both validation cohorts and an association with loss of ER 
expression levels on all three breast cohorts. Using expression levels of three epitopes, we can begin to 
assess the likelihood of delayed time to fixation or decreased tissue quality. This TQI represents a proof of 
concept for the use of epitope expression to provide a mechanism for monitoring tissue quality. 
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Over the past 5–10 years there have been a number of events that have caused concern related to quality 
assurance in laboratories performing diagnostic testing in oncology and the accuracy of these tests, which 
ultimately determine patient therapy.1 Our field has recognized the danger in the lack of standardization of 
processes between different laboratories, the variability inherent in the analytical phase and the lack of 
control over the preanalytical phase of tissue processing. Biospecimen science, the study of variables 
affecting biospecimen analysis, has identified a range of factors affecting the quality of harvested tissue.2, 3, 
4, 5 These factors, grouped as preanalytical variables, represent a critical problem for biomarker 
measurement on tissue specimens that can lead to errors that affect patient care. 
This issue is most prominent in breast cancer where it has been shown that preanalytical variables, 
especially delayed time to formalin fixation (cold ischemic time), have affected companion diagnostic 
testing.6, 7, 8, 9 Overall, it has been estimated that delay to formalin fixation and subsequent protein 
degradation within the tissue are responsible for a 10–20% false-negative rate for ER in breast cancer.1, 9 A 
similar effect has been shown for HER2 with loss of protein and RNA as a function of increasing time to 
fixation of the tissue. These issues have prompted the American Society of Clinical Oncologists (ASCO) and 
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the College of American Pathologists (CAP) to publish guidelines for the evaluation of ER, PgR and Her2 in 
breast cancer, limiting cold ischemic time to 60min.10, 11 
The issue of preanalytic variables is not limited to the companion diagnostics of breast cancer. Data have 
been published about the loss of antigenicity of phosphorylated proteins12, 13, 14, 15 and increased levels of 
hypoxia-induced factors, as well as markers of post-translational modification as a consequence of delayed 
time to formalin fixation of harvested tissue.16 Also, RNA degradation and time-dependent modulation of 
gene expression have been observed as a cellular reaction to stress and suboptimal preanalytical 
processing conditions.15 Finally, the effects of preanalytical variables on harvested tissue do not only have 
an important role for companion diagnostic testing and development of new drugs but also in retrospective 
studies using archived tissue collections, where documentation of tissue handling and processing is often 
minimal. 
Therefore, it was our goal to develop and construct an intrinsic control for formalin-fixed, paraffin-embedded 
(FFPE) tissue that could be used to assess suitability of a given specimen of unknown quality for 
immunological assessments. Here we describe proof of concept for the development of a tissue quality index 
(TQI). 
Materials and Methods 
Study Cohorts 
This prospectively designed study included three different cohorts of breast tissue, all of which have exact 
information on preanalytical specimen handling and processing with focus on cold ischemic time. All tissue 
was used after approval from the Rochester Institutional Review Board, from the Yale Human Investigation 
Committee protocol no. 8219 or no. 25173, or from the ethic institutional review board for ‘Biobanking and 
use of human tissue for experimental studies’ of the Pathology Services of the Azienda Ospedaliera Città 
della Salute e della Scienza di Torino. Written informed consent was obtained from all patients for their 
tissue to be used in research. 
Time to Fixation Breast Cancer Series 
Formalin-fixed, paraffin-embedded (FFPE) tissues of 93 breast cancer patients, who underwent surgery at 
the University of Rochester, School of Medicine (Rochester, NY, USA), were collected. Time from surgical 
resection to immersion of the specimen in formalin was recorded and ranged from 25 to 415 min. A tissue 
microarray (TMA) was constructed, consisting of these 93 breast cancer specimens, cell lines, and controls, 
all represented in twofold redundancy (two histospots per patient specimen). 
Normal Breast Tissue Series 
Normal breast tissues (NBTs) from 11 breast reduction mammoplasties were collected. Tissue from each 
patient was divided into different parts and exposed to predefined and controlled preanalytical variables, with 
time points until immersion of the tissue into formalin at 20min and 2, 24 and 48h after surgical removal of 
the tissue. A TMA was constructed representing these specimens with variable conditions in fourfold 
redundancy. 
Italian Breast Cancer Series 
Tissues from 100 breast cancer cases were collected and time until formalin fixation of these tissues was 
recorded, ranging from 1 to 72h. This cohort differs from the time to fixation breast cancer (TFBC) series in 
a way that tissues were vacuum sealed and stored at 4°C (UVSC) right after surgical removal until gross 
dissection and immersion of the tissue into formalin.17 TMAs were constructed consisting of the 100 breast 
cancer specimens represented in twofold redundancy. 
Cell lines and cell culture 
The cell lines T47D, BT474, SKBR3, MB231, MB468, CHO, A431, HT29, A59-195, and A82-68-B were 
purchased from ATCC (Manassas, VA, USA), cultured in our lab, and used to create control cell line cell 
blocks for TMA standardization. Culture conditions and construction of cell pellets for TMAs have been 
described previously.18 
TMA construction 
The TMAs for the three breast tissue series were constructed as described previously.18 Representative 
areas from the FFPE breast tissue were placed in a recipient block using 0.6mm cores for the TFBCS and 
the NBT sets and using 1mm cores for the Italian Breast Cancer (IBC) series. 
Antibodies, immunofluorescent staining, and quantitative analysis using the AQUA method 
These methods are all described in our previous work.9 
Statistical analysis 
TQI design: The goal of this procedure was to identify pairs of markers such that the difference between their 
AQUA scores is indicative of the time to fixation of the corresponding tissue. To simplify the design, we 
divided the times to fixation in two groups, according to whether the time was longer or shorter than 60 min, 
which was roughly the median time to fixation in our data set. We divided our data set into three groups, two 
of which were used for training and one was used as the test set. We used the training set to construct and 
screen prediction rules for the time to fixation. We then selected the six prediction rules with the largest 
training performance and computed their test performance. Using the training set, for each pair of markers j 
and k computed a screening score based on the differences of AQUA scores for the two markers across all 
patients as follows:  
 
Sjk= [(xij−xik)log2(ti/60)]                   
 
 
where N is the number of samples (patients) in the training set, xij and xik are the AQUA scores of markers j 
and k for sample (patient) i, and ti is the time to fixation in minutes for sample (patient) i. The difference is 
weighted by the term log2(ti/60), which was used to favor pairs of markers whose difference had a different 
sign depending on whether the time to fixation was longer or shorter than 60 min. The formulation as 
log2(ti/60) was chosen to reduce contributions to the score from samples with time to fixation around 60 min, 
and thus reduced the effects of time measurement precision on defining whether a time to fixation was 
longer or shorter than 60 min. The logarithm was introduced to reflect the notion of exponential decays in 
markers half-lives, as well as the desired change of sign in the difference of AQUA scores in samples with 
time to fixation larger than the reference time of 60min. The hyperbolic tangent represents a smooth 
threshold to limit spurious outliers. For each pair of markers, j and k, we derived a prediction rule Rjk. The 
rule Rjk predicts that the time to fixation is larger than 60min when the AQUA score of marker j is larger 
than the AQUA score of marker k. For each prediction rule Rjk, we computed its performance using the area 
under the curve (AUC) of a receiver-operator characteristic curve on the training set. The AUC measured the 
ability of the difference between the AQUA scores of two chosen markers to classify correctly whether a TTF 
was longer or shorter than 60 min. Finally, we determined the test performance of the six rules with the 
largest training performance by computing their AUC on the test data. The chosen design addresses the 
inherent variability of biological samples by comparing two markers at a time. Our procedure favored pairs of 
markers such that the AQUA score of one increases with time to fixation, while the other decreases. For 
further validation of the TQI performance linear regressions were computed for log2-transformed time to 
fixation and the TQI components. 95% CIs were calculated using the bootstrapping approach (n=5000). 




Quantification of Protein Expression According to Delayed Time to Formalin Fixation 
To construct the TQI, the antibodies described in Table 1 were all tested on the TFBC series and their 
expression levels and possible changes as a function of preanalytical variables were measured. These 
results have been described previously.16 Briefly, housekeeping genes do not lose antigenicity with 
increasing time to formalin fixation, while proteins of hypoxia and some post-translational modifications 
significantly increase in expression. Other biomarkers, such as phosphotyrosine or phospho-Erk1/2 are more 
labile and show significant degradation with increasing time to fixation. 
Table 1. Antibodies tested for the TQI 
  Antibody  
Symbol Description Clone/Isotype Supplier 
Markers of Cold Ischaemia 
ACTB Beta-Actin 13E5/IgG Cell Signaling Technology 
TUBB Beta-Tubulin pF3/IgG Cell Signaling Technology 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
14C10/IgG Cell Signaling Technology 
HIST4 Histone 4  L64C1 Cell Signaling Technology 
HIST3 Histone 3 96C10/IgG1 kappa Cell Signaling Technology 
LMNA/C Lamin A/C Polyclonal Cell Signaling Technology 
LDHA Lactat Dehydrogenase IgG, C4B5 Cell Signaling Technology 
ERalpha Estrogen Receptor alpha SP1/IgG Thermo Scientific 
CK Cytokeratin AE1/AE3/IgG1 DAKO 
CK Cytokeratin Polyclonal DAKO 
ERK1/2 P44/42MAPK (Erk1/2) 137F5, IgG Cell Signaling Technology 
p53 Anti-Human p53 protein IgG2b. DO-7 DAKO 
Markers of Hypoxia 
CCND1 Cyclin D1 IgG/SP4 Thermo Fisher Fremont 
Caspase Cleaved Caspase 3 (Asp175) Polyclonal Cell Signaling Technology 
HIF1 Hypoxia Inducible Factor 1 Polyclonal Novus Biological 
AKAP13 A-kinase anchoring protein 13 IgG2a/ZX-18 Santa Cruz Biotechnology 
CDC42  IgG3/B-8 Santa Cruz Biotechnology 
CCNB1 Cyclin B1  GNS-11/IgG2 BD Biosciences 
HIF-2alpha Hypoxia inducible factor-2α ep190b/IgG1 Abcam 
CA9 Carbonic Anhydrase IX Polyclonal(aa581-592) Lifespan Biosciences 
Markers of phosphorylated proteins 
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pAKT 473 phospho-Akt (ser473) D9E/IgG Cell Signaling Technology 
ERK1/2 Phospho-p44/43MAPK 
(Erk1/2) (Thr292/Tyr204) 
IgG Cell Signaling Technology 
pER Phospho-Estrogen Receptor 
alpha (Ser118) 
16J4/IgG2b Cell Signaling Technology 
Anti-Phosphotyrosine 4G10 Anti-Phosphotyrosine IgG2b Millipore 
Anti-Phosphotyrosine  p-Tyr-100 Cell Signaling Technology 
pHSP27 (pS78) Phosphorylated Heat Shock 
Protein 27 
Y175 Epitomics 
pHer2 (Tyr1248) Phospho-Her2/ErbB2 
(Tyr1248) 
PN2A Thermo Scientific 
Phospho-Stat3 (Tyr705) Phospho-Stat3 (Tyr705) D3A7/IgG Cell Signaling Technology 




D52.2.2E/IgG Cell Signaling Technology 
Phospho-Jak2 (Tyr1007/1008) Phospho-Jak2 (Tyr1007/1008) Polyclonal Cell Signaling Technology 
Phospho-Met (Tyr1234/1235) Phospho-Met (Tyr1234/1235) IgG Cell Signaling Technology 
Phospho-Sapk/Jnk Phospho-Sapk/Jnk IgG Cell Signaling Technology 
Phospho mTor (Ser2448) Phospho mTor (Ser2448) 49F9/IgG Cell Signaling Technology 
Markers of posttranslational modification 
Sumo1 small ubiquitin related modifier 
1 
Y299/IgG Abcam 
Acetylated-Lysine Proteins posttranslat. Modified 
by acetylation 
Polyclonal, purified Cell Signaling Technology 
NEDD8 Neural precursor cell-expr. 
devel. Downreg. protein9 




The TQI as an Intrinsic Control to Assess Delay to Formalin Fixation 
The TQI was constructed using a subset of the TFBC series and its performance measured on a validation 
subset of the same array. Construction and performance of the TQI are described in Figure 1. The best 
candidate TQIs consisted of five pairwise combinations of proteins. The AQUA scores of all proteins were 
log2 transformed and subtracted from each other, with phosphotyrosine:phospho-HSP27 (pHSP27) 
performing best, the AUC value being 0.75, followed by cytokeratin:pHSP27 and ERK1/2:pHSP27 with 
training set AUC values between 0.6 and 0.7 (Figure 1a) and testing set somewhat lower. The predictive 
value of the TQI regarding delayed time to fixation was then assessed on the complete TFBC series (Figures 
1b and c). A negative TQI value means that log2-normalized AQUA scores of pHSP27 are higher than the 
log2-normalized AQUA scores of phosphotyrosine or cytokeratin or ERK1/2. This suggests that the tissue 
may have suffered loss of antigenicity caused through delay in formalin fixation or other less well-defined 
preanalytic variables. The number of specimens with negative TQI values appears to be associated with 
prolonged cold ischemic time on the TFBC series. 
 
 
a.The performance of six marker combinations on the testing and validation subgroup of the time to 
fixation breast cancer series as measured by receiver-operator characteristic (ROC) curves and area 
under the curve (AUC) values. The tissue quality index (TQI) was then calculated on the complete time 
to fixation breast cancer series. (b) TQI values of cytokeratin:pHSP27 and (c) ERK1/2:pHSP27 in 
relationship with increasing cold ischemic time. 
Validation of the TQI on Two Independent Breast Tissue Validation Cohorts 
We then validated the TQI and its performance on two independent cohorts of breast tissue, the NBT series 
and the IBC series, both of which consist of breast tissue with recorded cold ischemic time. Owing to the lack 
of lot-to-lot reproducibility of all tested phosphotyrosine antibody cocktails, and/or high levels of 
heterogeneity of the proteins targeted by this antibody, we were not able to reproduce our original results for 
phosphotyrosine and therefore omitted this epitope from the TQI. The other biomarkers, pHSP27, 
cytokeratin, and ERK1/2 showed robust reproducibility and were used in the validation of the TQI. 
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Before assessing the validation cohorts, we tested the TQI on a unique build (different TMA master block) of 
the TFBC series, which had initially served as the train/test cohort. We were able to show reproducibility of 
our original result, suggesting that this TQI is independent of biomarker heterogeneity seen for cytokeratin, 
ERK1/2, and pHSP27. The performance of the TQI was also validated and measured on this new build of 
the TFBC series. Linear regressions between increasing time to fixation and the differences of AQUA scores 
of the TQI markers were computed. Larger differences of the TQI makers correspond with shorter time to 
fixation measures for a time window of 30 to 120min (Figure 2a). 
Validation and performance of the tissue quality index (TQI) on the time to fixation breast cancer (TFBC), the 
normal breast tissue (NBT), and Italian breast cancer (IBC) series. (a) Linear regressions between increasing 
time to fixation (log2 transformed) and the differences of AQUA scores of the TQI markers as performance 
measurement on an independent built of the TFBC. Higher values correspond with shorter time to fixation. 
The dotted line shows the 95% confidence interval (CI) of the regression line. (b) TQI pairs on each time-
point of the NBT series. (c) Chi-squared analysis of the different TQI components. Although each marker 
combination by itself shows a significant correlation to increasing cold ischemic time, the combination of the 
separate TQI components facilitates the identification of a larger number of samples, which may have 
compromised tissue quality. (d) The TQI performance on the IBC series where special fixation conditions 
appears to result in significantly less epitope degradation. 
This proof of principle was followed by validation on the NBT series and the IBC series. Negative TQI values 
are correlated with increasing delay to formalin fixation on the NBT series, indicating potential for detection of 
preanalytic epitopic degradation (Figure 2b). Chi-square analysis of each TQI and the combination of both 
shows a statistically significant association with time to fixation in this series (Figure 2c). The performance of 
the TQI on build 2 of the TFBC series and the NBT series was also assessed by calculation of the AUC of an 
ROC curve and showed values of 0.6–0.7 for these marker combinations recapitulating our original result 
(not shown). The IBC series consists of patient samples, which were vacuum sealed and stored at 4°C 
(UVSC) to prevent degradation. Although this is not the current standard of care, we used this cohort as this 
method represents an alternative approach to diminishing the effects of cold ischemic time. The 
quantification of pHSP27, cytokeratin, and ERK1/2 and calculation of the TQI revealed mainly positive TQI 
scores (147 out of 169 readable samples have a positive TQI—the series consists of 100 patients, 
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represented in twofold redundancy on the TMAs) suggesting better preservation of the tissue through 
vacuum sealing and storage at 4°C (Figure 2d). 
TQI Value and Quantitative ER Expression in Breast Tissue 
Recent publications have shown that there is no loss of ER expression for tissue fixed within 1h of cold 
ischemic time.16. However, loss of ER antigenicity has been reported for longer cold ischemic times.6, 9 
Here we determine if the TQI can indicate loss of ER reactivity. Specifically, we hypothesize that cases with 
a negative TQI should have lower ER scores. ER was measured by QIF with the clone SP1 on all three 
breast tissue series. We showed that negative TQI values are significantly correlated with lower ER AQUA 
scores on the NBT series and the IBC series (Figures 3a and b), with P-values of 0.03. The correlation of 
TQI values and ER AQUA scores on build 2 of the TFBC series trends toward significance (P=0.067), but the 
majority of samples in this series were formalin fixed within 2h. The expression levels of the proteins 
included in this TQI (pHSP27, cytokeratin, and ERK1/2) do not show any correlation with ER expression as 
tested by Pearson’s correlation coefficient of each protein separately (data not shown). Thus, the association 
of the TQI and ER AQUA scores appears to be a function of tissue quality and not a coincidental correlation 
of the TQI proteins and ER expression. 
 
 
Measurement of the tissue quality index (TQI) performance as a function of estrogen receptor (ER) 
expression levels quantified by AQUA. Negative TQI values are significantly associated with lower ER AQUA 
scores on the normal breast tissue (NBT) series and the Italian breast cancer (IBC) series (a and b), while 
the correlation between TQI values and ER expression does not reach significance on build 2 of the time to 
fixation breast cancer (TFBC) series. 
DISCUSSION 
A clinical mishap in Canada and a series of papers focusing on preanalytic variables have illustrated the 
need for a mechanism for tissue quality assessment.2, 5, 19 In response to these reports and new ER, PR, 
and HER2 guideline recommendations from the ASCO/CAP panel, efforts have been made to control 
preanalytical variables, especially cold ischemic time, to standardize companion diagnostic testing.10, 11 
However, these standards cannot always be met and clinicians and researchers are often confronted with 
the challenge of accurate molecular characterization of tissue samples of unknown quality. Here we describe 
for the first time the construction of an internally calibrated tool consisting of three epitopes and their relative 
changes to assess the effects of cold ischemic time and the suitability of a given tissue for further 
immunological assessments. 
Although substantial efforts in our field have improved standardization and documentation of tissue 
harvesting and companion diagnostic testing, controlling and minimizing preanalytical variables on tissue is 
still problematic and it is not hard to imagine a situation in which a TQI is needed. If for example, a breast 
cancer specimen of unknown quality tests negative for ER, one could envision assessment of the TQI to 
discount false-negative results caused through protein degradation. The TQI could also be envisioned to be 
applied to all specimens received for a clinical trial where tissue is collected from a wide range of sites 
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around the world with less standardized laboratory settings. In this context, the TQI could prove that the 
tissue had the capacity to inform for the companion diagnostic test or it could suggest elimination of that data 
point in the subsequent biomarker analysis owing to poor tissue quality. Finally, the TQI could be used on 
retrospective studies based on archived tissue collections where information on postsurgical tissue 
processing was not available. In each case, testing the quality of the tissue could provide better accuracy, 
reproducibility, and applicability for research based on in situ biomarker evaluation. 
Although the antibodies used for construction of the TQI were validated and the results of the TQI and its 
relationship to prolonged cold ischemic time and ER expression levels were reproducible on different breast 
tissue series, our work should be considered as pilot data and a proof of concept, rather than a definitive TQI 
test. This first study is subject to a number of limitations. Perhaps, the most significant is the low sensitivity 
and specificity for prediction. The performance of the two marker combinations—cytokeratin:pHSP27 and 
ERK1/2:pHSP27—as measured by AUC value, ranges from 0.6 to 0.7 showing the assay is accurate only 
between two-third and three-fourth of the times. Even though the TQI value is significantly correlated with 
increasing cold ischemic time, a performance of 0.6–0.7 AUC value suggests that several specimens in 
these breast tissue series are misclassified with respect to their potential loss of antigenicity. 
A second major limitation of this TQI test is that it was constructed using only breast cancer tissues. Although 
it validated on two independent tissue sets, the IBC series were subject to different preanalytical variables 
(UVSC conditions),17 resulting in better preservation of biomarker expression as compared with the other two 
breast tissue series. In the future, we envision applicability of future TQIs in many other tissue types. 
Finally, any TQI will always be limited by the variability in the epitope degradation rate between different 
epitopes. Here, we focused on ER, where we observed a significant association of lower ER expression 
levels with negative TQI values in two out of the three breast cohorts used for this study. However, the TQI 
might be better or worse if other epitopes were assessed. It is possible that to be highly accurate in 
assessment of tissue quality, a unique index may be required for certain classes of proteins or even for 
individual proteins. For example, phosphoepitopes on tyrosine appear to be highly labile and might require a 
different TQI than more stable structural proteins like tubulin or actin. 
The variable rate of degradation of epitopes raises the question of the time window for the TQI. It has been 
previously shown that the bulk of the degradation of ER does not occur within the first few hours of delay to 
formalin fixation but rather at a later time window.6, 8, 9 This observation may explain why we did not observe 
a significant loss of ER AQUA scores for patients with a negative TQI on the TFBC series where most of the 
cases were fixed within 2h. In comparison, in the longer NBT and IBC sets, where delay to fixation was 
stretched to 48h or more, the TQI performed better. In the future one can envision different TQIs constructed 
for different time windows, depending on the specific projected application for the TQI. 
 
In summary, for the first time, we report the construction of a TQI that serves as an intrinsic control of tissue 
quality. Although this work is preliminary and further optimization of this TQI is necessary to improve its 
performance and applicability to multiple tissue types, it represents a proof of concept for the potential for 
quantitative quality assessment of tissue specimens. We are hopeful that this approach to quantitative 
measurement of three or four biomarkers and their relative changes/relationships to each other can provide 
a tool to monitor effects of preanalytical variables on tissue specimens. In the future, we believe we will see 
more sensitive and specific tools for assessment of tissue quality. 
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